Filing Flows › Comparisons › HIND vs ALT
Vyome Holdings vs Altimmune: HIND and ALT compared
Vyome Holdings is the larger company: $27K of revenue in its latest quarter (Q2 2026) against $26K for Altimmune (Q4 2025). Altimmune is growing faster (+420% against -46% a year earlier).
Where the money goes: HIND and ALT
Vyome Holdings (HIND) · Q2 2026
Vyome Holdings, Q2 2026: revenue $27K (-46% year over year), net loss $720K, operating cash flow −$904K. The chart follows the revenue to costs, profit and cash.
Altimmune (ALT) · Q4 2025
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
| Vyome Holdings (HIND) | Altimmune (ALT) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2025 |
| Revenue | $27K | $26K |
| Revenue growth, Y/Y | -46% | +420% |
| Operating margin | n/m | n/m |
| Net earnings | −$720K | −$27.4M |
| Operating cash flow | −$904K | −$19.4M |
Questions
Which is bigger, Vyome Holdings or Altimmune?
Vyome Holdings is the larger company: $27K of revenue in its latest quarter (Q2 2026) against $26K for Altimmune (Q4 2025).
Is Vyome Holdings or Altimmune growing faster?
Altimmune is growing faster (+420% against -46% a year earlier).
More: Vyome Holdings earnings · how Vyome Holdings makes money · Altimmune earnings · how Altimmune makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-K filed Mar 6, 2026). Fiscal quarters can end on different dates. Not investment advice.